Follow-Up and Management of Young Adults with Steroid-Sensitive Nephrotic Syndrome

Monitoring and Definition of Remission

The International Society of Nephrology recommends that young adults with SSNS who have achieved remission should be monitored with regular urine dipstick testing for proteinuria at home and periodic clinical assessments, with the frequency and duration of follow-up determined by their relapse pattern and steroid dependence status 1, 2
Remission is confirmed when urine dipstick shows trace/negative proteinuria for at least 3 consecutive days, according to the Kidney Disease: Improving Global Outcomes (KDIGO) guideline 1, 2, 3
Home urine dipstick testing should be performed regularly (at minimum weekly, more frequently during intercurrent illnesses) to detect early relapse, as recommended by the American Society of Nephrology 2, 3
Relapse is defined as ≥2+ proteinuria for 3 consecutive days on early morning urine or ≥2+ proteinuria with edema, as defined by the National Kidney Foundation 1

For patients on calcineurin inhibitors who achieved complete remission, the American College of Physicians recommends considering discontinuation after 12-24 months to reduce nephrotoxicity risk 2, 4
Monitor serum creatinine and estimated GFR to assess for CNI nephrotoxicity, as recommended by the National Institute of Diabetes and Digestive and Kidney Diseases 2, 4

The American Academy of Pediatrics recommends that during upper respiratory tract infections or other illnesses, patients with frequent relapsing or steroid-dependent SSNS should receive daily prednisone at their maintenance dose to reduce relapse risk 5

The European Renal Association recommends treating infrequent relapses with prednisone 60 mg/m² (maximum 60 mg/day) daily until remission for at least 3 days, then 40 mg/m² on alternate days for at least 4 weeks 1, 5
For frequent relapses or steroid-dependent disease, the International Society of Nephrology recommends switching to alternate-day therapy for at least 3 months after achieving remission with daily prednisone 1, 2, 5
The American Society of Nephrology recommends considering steroid-sparing agents (levamisole first-line, then cyclophosphamide or CNIs) if patients develop steroid-related adverse effects or meet criteria for frequent relapsing/steroid-dependent disease 1, 2, 5

The National Kidney Foundation recommends not continuing CNIs indefinitely - reassess need after 12-24 months of complete remission to minimize nephrotoxicity 2, 4
The American Journal of Kidney Diseases recommends not using cyclophosphamide for steroid-resistant nephrotic syndrome if it develops - CNIs are first-line therapy 2, 6